Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome

Lupus Sci Med. 2022 Jan;9(1):e000630. doi: 10.1136/lupus-2021-000630.

Authors

Bonnie Bermas¹, Nathalie Costedoat-Chalumeau^{2

3}

Affiliations

¹ Division of Rheumatic Diseases, UT Southwestern Medical, Dallas, Texas, USA [email protected].
² Service de médecine interne, Centre de référence maladies autoimmunes et systémiques rares Île de France, APHP, Hopital Cochin, Paris, France.
³ Université de Paris, Centre de recherche épidémiologie et biostatistiques de Sorbonne Paris Cité, F-75004 Paris, France.

No abstract available

Keywords: antirheumatic agents; lupus erythematosus; pharmacokinetics; systemic.

Publication types

Kommentar

MeSH terms

Antirheumatic Agents* / therapeutic use
Female
Humans
Hydroxychloroquine / therapeutic use
Infant, Newborn
Lupus Erythematosus, Systemic* / drug therapy
Pregnancy

Substances

Antirheumatic Agents
Hydroxychloroquine